Skip to main content
Top
Published in: Annals of Hematology 9/2014

01-09-2014 | Original Article

Is it really possible to cure hairy cell leukemia patients only with frontline therapy?

Authors: Pier Luigi Zinzani, Vittorio Stefoni, Alessandro Broccoli, Cinzia Pellegrini, Letizia Gandolfi, Beatrice Casadei, Roberto Maglie, Stefano Pileri, Lisa Argnani

Published in: Annals of Hematology | Issue 9/2014

Login to get access

Abstract

Hairy cell leukemia (HCL) patients could have an excellent prognosis with adequate treatment. Treatments are not generally curative but are extremely effective in inducing long-lasting clinical remissions. An observational retrospective study was conducted on a single-center registry of 144 patients with a median follow-up of 11.5 years, focusing on long-lasting continuous first complete remissions (CR) wondering if patients can be cured only with front-line approach. CR for more than 5 years after first-line therapy were found in 22.2 % cases. The median duration of response was 9.8 years, while for relapsed patients, the first response had a median duration of 2.4 years. Three different subsets of long-lasting first CR were identified: 15 patients are between 5 and 10 years with a median duration of CR of 6.5 years; 7 patients are between 10 and 15 years with a median duration of CR of 12.3 years; and 10 patients present a follow-up superior to 15 years with a median duration of CR of 20.0 years. There is a need for continuous study in this field to better define the optimal therapeutic regimen and, in particular, the biological issues since at least 20–25 % of HCL patients can be cured with only one treatment.
Literature
1.
go back to reference Golde DW, Weiss MA (2000) Hairy cell leukemia, an historical perspective. In: Tallman M, Polliack A (eds) Hairy cell leukemia. Harwood Academic, The Netherlands, pp 1–8 Golde DW, Weiss MA (2000) Hairy cell leukemia, an historical perspective. In: Tallman M, Polliack A (eds) Hairy cell leukemia. Harwood Academic, The Netherlands, pp 1–8
2.
go back to reference Golomb HM, Catovsky D, Golde DW (1978) Hairy cell leukaemia: a clinical review based on 71 cases. Ann Intern Med 81:677–683CrossRef Golomb HM, Catovsky D, Golde DW (1978) Hairy cell leukaemia: a clinical review based on 71 cases. Ann Intern Med 81:677–683CrossRef
3.
go back to reference Berman E, Heller G, Kempin S, Gee T, Tran LL, Clarkson B (1990) Incidence of response and long-term follow-up in patients with hairy cell leukemia treated with recombinant interferon alfa-2a. Blood 75:839–845PubMed Berman E, Heller G, Kempin S, Gee T, Tran LL, Clarkson B (1990) Incidence of response and long-term follow-up in patients with hairy cell leukemia treated with recombinant interferon alfa-2a. Blood 75:839–845PubMed
4.
go back to reference Grever M, Kopecky K, Foucar MK, Head D, Bennett JM, Hutchison RE, Corbett WE, Cassileth PA, Habermann T, Golomb H (1995) Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol 13:974–982PubMed Grever M, Kopecky K, Foucar MK, Head D, Bennett JM, Hutchison RE, Corbett WE, Cassileth PA, Habermann T, Golomb H (1995) Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol 13:974–982PubMed
5.
go back to reference Federico M, Frassoldati A, Lamparelli T, Foà R, Brugiatelli M, Annino L, Baldini L, Capnist G, Chisesim T, di Celle PF (1994) Long-term results of alpha interferon as initial therapy and splenectomy as consolidation therapy in patients with hairy cell leukemia. Final report from the Italian Cooperative Group for HCL. Ann Oncol 5:725–731PubMed Federico M, Frassoldati A, Lamparelli T, Foà R, Brugiatelli M, Annino L, Baldini L, Capnist G, Chisesim T, di Celle PF (1994) Long-term results of alpha interferon as initial therapy and splenectomy as consolidation therapy in patients with hairy cell leukemia. Final report from the Italian Cooperative Group for HCL. Ann Oncol 5:725–731PubMed
6.
go back to reference Flandrin G, Sigaux F, Sebahoun G, Bouffette P (1984) Hairy cell leukemia: clinical presentation and follow-up of 211 patients. Semin Oncol 11:458–471PubMed Flandrin G, Sigaux F, Sebahoun G, Bouffette P (1984) Hairy cell leukemia: clinical presentation and follow-up of 211 patients. Semin Oncol 11:458–471PubMed
7.
go back to reference Spiers AS, Moore D, Cassileth PA, Harrington DP, Cummings FJ, Neiman RS, Bennett JM, O'Connell MJ (1987) Remissions in hairy-cell leukemia with pentostatin (20-deoxycoformycin). N Engl J Med 316:825–830PubMedCrossRef Spiers AS, Moore D, Cassileth PA, Harrington DP, Cummings FJ, Neiman RS, Bennett JM, O'Connell MJ (1987) Remissions in hairy-cell leukemia with pentostatin (20-deoxycoformycin). N Engl J Med 316:825–830PubMedCrossRef
8.
go back to reference Piro LD, Carrera CJ, Carson DA, Beutler E (1990) Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 322:1117–1121PubMedCrossRef Piro LD, Carrera CJ, Carson DA, Beutler E (1990) Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 322:1117–1121PubMedCrossRef
9.
go back to reference Dearden CE, Matutes E, Hilditch BL, Swansbury GJ, Catovsky D (1999) Long-term follow-up of patients with hairy cell leukaemia after treatment with pentostatin for cladribine. Br J Haematol 106:515–519PubMedCrossRef Dearden CE, Matutes E, Hilditch BL, Swansbury GJ, Catovsky D (1999) Long-term follow-up of patients with hairy cell leukaemia after treatment with pentostatin for cladribine. Br J Haematol 106:515–519PubMedCrossRef
10.
go back to reference Chadha P, Rademaker AW, Mendiratta P, Kim B, Evanchuk DM, Hakimian D, Peterson LC, Tallman MS (2005) Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience. Blood 106:241–246PubMedCrossRef Chadha P, Rademaker AW, Mendiratta P, Kim B, Evanchuk DM, Hakimian D, Peterson LC, Tallman MS (2005) Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience. Blood 106:241–246PubMedCrossRef
11.
go back to reference Maloisel F, Benboubker L, Gardembas M, Coiffier B, Divine M, Sebban C, Blanc M, Abgrall JF, Lederlin P, Harousseau JL, Blaise AM, Grosbois B, Morice P, Ghandour C, Castaigne S (2003) Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients. Leukemia 17:45–51PubMedCrossRef Maloisel F, Benboubker L, Gardembas M, Coiffier B, Divine M, Sebban C, Blanc M, Abgrall JF, Lederlin P, Harousseau JL, Blaise AM, Grosbois B, Morice P, Ghandour C, Castaigne S (2003) Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients. Leukemia 17:45–51PubMedCrossRef
12.
go back to reference Rafel M, Cervantes F, Beltran JM, Zuazu F, Hernández Nieto L, Rayón C, García Talavera J, Montserrat E (2000) Deoxycoformycin in the treatment of patients with hairy cell leukemia: results of a Spanish collaborative study of 80 patients. Cancer 88:352–357PubMedCrossRef Rafel M, Cervantes F, Beltran JM, Zuazu F, Hernández Nieto L, Rayón C, García Talavera J, Montserrat E (2000) Deoxycoformycin in the treatment of patients with hairy cell leukemia: results of a Spanish collaborative study of 80 patients. Cancer 88:352–357PubMedCrossRef
13.
go back to reference Zinzani PL, Tani M, Marchi E, Stefoni V, Alinari L, Musuraca G, Gabriele A, Pileri S, Baccarani M (2004) Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine. Haematologica 89:309–313PubMed Zinzani PL, Tani M, Marchi E, Stefoni V, Alinari L, Musuraca G, Gabriele A, Pileri S, Baccarani M (2004) Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine. Haematologica 89:309–313PubMed
14.
go back to reference Flinn IW, Kopecky KJ, Foucar MK, Head D, Bennett JM, Hutchison R, Corbett W, Cassileth P, Habermann T, Golomb H, Rai K, Eisenhauer E, Appelbaum F, Cheson B, Grever MR (2000) Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood 96:2981–2986PubMed Flinn IW, Kopecky KJ, Foucar MK, Head D, Bennett JM, Hutchison R, Corbett W, Cassileth P, Habermann T, Golomb H, Rai K, Eisenhauer E, Appelbaum F, Cheson B, Grever MR (2000) Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood 96:2981–2986PubMed
15.
go back to reference Jehn U, Bartl R, Dietzfelbinger H, Haferlach T, Heinemann V (2004) An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine. Leukemia 18:1476–1481PubMedCrossRef Jehn U, Bartl R, Dietzfelbinger H, Haferlach T, Heinemann V (2004) An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine. Leukemia 18:1476–1481PubMedCrossRef
16.
go back to reference Else M, Ruchlemer R, Osuji N, Del Giudice I, Matutes E, Woodman A, Wotherspoon A, Swansbury J, Dearden C, Catovsky D (2005) Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years. Cancer 104:2442–2448PubMedCrossRef Else M, Ruchlemer R, Osuji N, Del Giudice I, Matutes E, Woodman A, Wotherspoon A, Swansbury J, Dearden C, Catovsky D (2005) Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years. Cancer 104:2442–2448PubMedCrossRef
17.
go back to reference Zinzani PL, Pellegrini C, Stefoni V, Derenzini E, Gandolfi L, Broccoli A, Argnani L, Quirini F, Pileri S, Baccarani M (2010) Hairy cell leukaemia: evaluation of the long-term outcome in 121 patients. Cancer 116:4788–4792PubMedCrossRef Zinzani PL, Pellegrini C, Stefoni V, Derenzini E, Gandolfi L, Broccoli A, Argnani L, Quirini F, Pileri S, Baccarani M (2010) Hairy cell leukaemia: evaluation of the long-term outcome in 121 patients. Cancer 116:4788–4792PubMedCrossRef
18.
go back to reference Else M, Dearden CE, Matutes E, Garcia-Talavera J, Rohatiner AZ, Johnson SA, O’Connor NT, Haynes A, Osuji N, Forconi F, Lauria F, Catovsky D (2009) Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol 145:733–740PubMedCrossRef Else M, Dearden CE, Matutes E, Garcia-Talavera J, Rohatiner AZ, Johnson SA, O’Connor NT, Haynes A, Osuji N, Forconi F, Lauria F, Catovsky D (2009) Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol 145:733–740PubMedCrossRef
19.
go back to reference di Celle PF, Reato G, Raspadori D, Carbone A, Rondelli D, Lauria F, Foà R (1994) Molecular evaluation of clonal remission in hairy cell leukemia patients treated with 2-chlorodeoxyadenosine. Leuk Lymphoma 14(Suppl 1):139–142PubMed di Celle PF, Reato G, Raspadori D, Carbone A, Rondelli D, Lauria F, Foà R (1994) Molecular evaluation of clonal remission in hairy cell leukemia patients treated with 2-chlorodeoxyadenosine. Leuk Lymphoma 14(Suppl 1):139–142PubMed
20.
go back to reference Ellison D, Sharpe R, Robbins B, Spinosa JC, Leopard JD, Saven A, Piro LD (1994) Immunomorphologic analysis of bone marrow biopsies after treatment with 2-chlorodeoxyadenosine for hairy cell leukaemia. Blood 84:4310–4315PubMed Ellison D, Sharpe R, Robbins B, Spinosa JC, Leopard JD, Saven A, Piro LD (1994) Immunomorphologic analysis of bone marrow biopsies after treatment with 2-chlorodeoxyadenosine for hairy cell leukaemia. Blood 84:4310–4315PubMed
21.
go back to reference Filleul B, Delannoy A, Ferrant A, Zenebergh A, Van Daele S, Bosly A, Doyen C, Mineur P, Glorieux P, Driesschaert P (1994) A single course of 2-chloro-deoxyadenosine does not eradicate leukemic cells in hairy cell leukemia patients in complete remission. Leukemia 8:1153–1156PubMed Filleul B, Delannoy A, Ferrant A, Zenebergh A, Van Daele S, Bosly A, Doyen C, Mineur P, Glorieux P, Driesschaert P (1994) A single course of 2-chloro-deoxyadenosine does not eradicate leukemic cells in hairy cell leukemia patients in complete remission. Leukemia 8:1153–1156PubMed
22.
go back to reference Consensus resolution: proposed criteria for evaluation of response to treatment in hairy cell leukemia (1987) Leukemia 1:405 Consensus resolution: proposed criteria for evaluation of response to treatment in hairy cell leukemia (1987) Leukemia 1:405
23.
go back to reference Dearden CE, Else M, Catovsky D (2011) Long-term results for pentostatin and cladribine treatment of hairy cell leukemia. Leuk Lymphoma 52(S2):21–24PubMedCrossRef Dearden CE, Else M, Catovsky D (2011) Long-term results for pentostatin and cladribine treatment of hairy cell leukemia. Leuk Lymphoma 52(S2):21–24PubMedCrossRef
24.
go back to reference Golomb HM, Vardiman JW (1983) Response to splenectomy in 65 patients with hairy cell leukaemia: an evaluation of spleen weight and bone marrow involvement. Blood 61:349–352PubMed Golomb HM, Vardiman JW (1983) Response to splenectomy in 65 patients with hairy cell leukaemia: an evaluation of spleen weight and bone marrow involvement. Blood 61:349–352PubMed
25.
go back to reference Quesada JR, Reuben JR, Manning JT, Hersh EM, Gutterman JU (1984) Alpha interferon for the induction of remission in hairy cell leukaemia. N Engl J Med 310:15–18PubMedCrossRef Quesada JR, Reuben JR, Manning JT, Hersh EM, Gutterman JU (1984) Alpha interferon for the induction of remission in hairy cell leukaemia. N Engl J Med 310:15–18PubMedCrossRef
26.
go back to reference Ratain MJ, Golomb HM, Vardiman JW, Vokes EE, Jacobs RH, Daly K (1985) Treatment of hairy cell leukaemia with recombinant alpha 2 interferon. Blood 65:644–648PubMed Ratain MJ, Golomb HM, Vardiman JW, Vokes EE, Jacobs RH, Daly K (1985) Treatment of hairy cell leukaemia with recombinant alpha 2 interferon. Blood 65:644–648PubMed
27.
go back to reference Kreitman RJ, Wilson WH, Bergeron K, Raggio M, Stetler-Stevenson M, FitzGerald DJ, Pastan I (2001) Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy- resistant hairy-cell leukemia. N Engl J Med 345:241–247PubMedCrossRef Kreitman RJ, Wilson WH, Bergeron K, Raggio M, Stetler-Stevenson M, FitzGerald DJ, Pastan I (2001) Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy- resistant hairy-cell leukemia. N Engl J Med 345:241–247PubMedCrossRef
28.
go back to reference Kreitman RJ, Squires DR, Stetler-Stevenson M, Noel P, FitzGerald DJ, Wilson WH, Pastan I (2005) Phase I trial of recombinant immunotoxin RFB4 (dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol 23:6719–6729PubMedCrossRef Kreitman RJ, Squires DR, Stetler-Stevenson M, Noel P, FitzGerald DJ, Wilson WH, Pastan I (2005) Phase I trial of recombinant immunotoxin RFB4 (dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol 23:6719–6729PubMedCrossRef
29.
go back to reference Ravandi F, Jorgensen JF, O’Brien SM, Verstovsek S, Koller CA, Faderl S, Giles FJ, Ferrajoli A, Wierda WG, Odinga S, Huang X, Thomas DA, Freireich EJ, Jones D, Keating MJ, Kantarjian HM (2006) Eradication of minimal residual disease in hairy cell leukemia. Blood 107:4658–4662PubMedCrossRef Ravandi F, Jorgensen JF, O’Brien SM, Verstovsek S, Koller CA, Faderl S, Giles FJ, Ferrajoli A, Wierda WG, Odinga S, Huang X, Thomas DA, Freireich EJ, Jones D, Keating MJ, Kantarjian HM (2006) Eradication of minimal residual disease in hairy cell leukemia. Blood 107:4658–4662PubMedCrossRef
30.
go back to reference Dietrich S, Glimm H, Andrulis M, von Kalle C, Ho AD, Zenz T (2012) BRAF inhibition in refractory hairy cell leukaemia. N Engl J Med 366:2038–2040PubMedCrossRef Dietrich S, Glimm H, Andrulis M, von Kalle C, Ho AD, Zenz T (2012) BRAF inhibition in refractory hairy cell leukaemia. N Engl J Med 366:2038–2040PubMedCrossRef
31.
go back to reference Peyrade F, Re D, Ginet C, Gastaud L, Allegra M, Ballotti R, Thyss A, Zenz T, Auberger P, Robert G (2013) Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation. Haematologica 98:20–22CrossRef Peyrade F, Re D, Ginet C, Gastaud L, Allegra M, Ballotti R, Thyss A, Zenz T, Auberger P, Robert G (2013) Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation. Haematologica 98:20–22CrossRef
32.
go back to reference Juliusson G, Samuelsson H, Swedish lymphoma registry (2011) Hairy cell leukaemia: epidemiology, pharmacokinetics of cladribine, and long-term follow up of subcutaneous therapy. Leuk Lymphoma 52(S2):46–49PubMedCrossRef Juliusson G, Samuelsson H, Swedish lymphoma registry (2011) Hairy cell leukaemia: epidemiology, pharmacokinetics of cladribine, and long-term follow up of subcutaneous therapy. Leuk Lymphoma 52(S2):46–49PubMedCrossRef
Metadata
Title
Is it really possible to cure hairy cell leukemia patients only with frontline therapy?
Authors
Pier Luigi Zinzani
Vittorio Stefoni
Alessandro Broccoli
Cinzia Pellegrini
Letizia Gandolfi
Beatrice Casadei
Roberto Maglie
Stefano Pileri
Lisa Argnani
Publication date
01-09-2014
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 9/2014
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-014-2081-5

Other articles of this Issue 9/2014

Annals of Hematology 9/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.